Musculoskeletal Disorders

Atom Bioscience reports positive Phase IIa chronic gout therapy trial data

Atom Bioscience has reported positive data from its China Phase IIa study of ABP-671 for the treatment of chronic gout.…

Incannex begins Phase II trial of combination drug for rheumatoid arthritis

Incannex Healthcare has commenced a Phase II clinical trial of its anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis…

Maze Therapeutics reports positive data from Pompe disease therapy trial

Maze Therapeutics has reported positive data from its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor MZE001 in…

Avidity reports data from Phase I/II myotonic dystrophy type 1 trial

Avidity Biosciences has reported positive initial analysis data from the Phase I/II MARINA clinical trial of AOC 1001 in adults…

Pipeline Moves: trial completions in glaucoma, lung, and oncology indications

This week on Pipeline Moves, we look into the completion of a Phase III trial in open-angle glaucoma. For Phase…

Peptilogics doses first subject in periprosthetic joint infection trial

Peptilogics has dosed the first subject in the Phase Ib LOGIC-1 clinical trial of investigational product PLG0206 to treat periprosthetic joint infections…

Avidity launches Phase I/II muscular dystrophy treatment trial

Avidity Biosciences has launched the Phase I/II FORTITUDE clinical trial of AOC 1020 in adult patients with facioscapulohumeral muscular dystrophy…

FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial

The US Food and Drug Administration (FDA) has placed a partial hold on Avidity Biosciences’ Phase I/II MARINA clinical trial of AOC…

Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial

Atamyo Therapeutics has dosed the first subject in a Phase I/II clinical trial of ATA-100 to treat FRKP-related limb-girdle muscular dystrophy type…

Santhera and ReveraGen dose first subject in Phase II trial of BMD drug

Santhera Pharmaceuticals and ReveraGen BioPharma have dosed the first subject in a Phase II pilot clinical trial of drug candidate…